Myles Selig Wolf, MD

Professor of Medicine
Member of the Duke Clinical Research Institute
Chief of Nephrology
Email address myles.wolf@duke.edu
Fax: 919-684-3011

The focus of my research is disordered mineral metabolism across the spectrum of chronic kidney disease, including dialysis, kidney transplantation and earlier stages.

My research has been published in leading general medicine and subspecialty journals, including the New England Journal of Medicine, JAMA, the Journal of Clinical Investigation, Circulation, Cell Metabolism, Journal of the American Society of Nephrology, and Kidney International, among others.

My primary contributions have been in the area of hormonal regulation of phosphate homeostasis. I have helped to characterize the physiological role of fibroblast growth factor 23 in health and in chronic kidney disease, and the impact of elevated fibroblast growth factor 23 levels on adverse clinical outcomes in patients with kidney disease.

Education and Training

  • Research Fellowship In Nephrology, Massachusetts General Hospital, 2000 - 2001
  • Clinical Fellowship In Nephrology, Brigham and Women's Hospital, 1999 - 2000
  • Internal Medicine Residency, Massachusetts General Hospital, 1996 - 1999
  • M.Med.Sc., Harvard Medical School, 2002
  • M.D., State University of New York at Brooklyn, 1996

Publications

Munoz Mendoza, J, Isakova, T, Cai, X, Bayes, LY, Faul, C, Scialla, JJ, Lash, JP, Chen, J, He, J, Navaneethan, S, Negrea, L, Rosas, SE, Kretzler, M, Nessel, L, Xie, D, Anderson, AH, Raj, DS, Wolf, M, and CRIC Study Investigators, . "Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease." Kidney international 91, no. 3 (March 2017): 711-719.

PMID
28017325
Full Text

Yuen, SN, Kramer, H, Luke, A, Bovet, P, Plange-Rhule, J, Forrester, T, Lambert, V, Wolf, M, Camacho, P, Harders, R, Dugas, L, Cooper, R, and Durazo-Arvizu, R. "Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization." The Journal of Clinical Endocrinology & Metabolism 101, no. 5 (May 2016): 2246-2253.

Full Text

Wright, CB, Shah, NH, Mendez, AJ, DeRosa, JT, Yoshita, M, Elkind, MSV, Sacco, RL, DeCarli, C, Rundek, T, Silverberg, S, Dong, C, and Wolf, M. "Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage." Stroke 47, no. 4 (April 2016): 923-928.

Full Text

Ali, FN, Josefson, J, Mendez, AJ, Mestan, K, and Wolf, M. "Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates." The Journal of Clinical Endocrinology & Metabolism 101, no. 4 (April 2016): 1673-1679.

Full Text

Leaf, DE, Christov, M, Jüppner, H, Siew, E, Ikizler, TA, Bian, A, Chen, G, Sabbisetti, VS, Bonventre, JV, Cai, X, Wolf, M, and Waikar, SS. "Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery." Kidney International 89, no. 4 (April 2016): 939-948.

Full Text

Scialla, JJ, and Wolf, M. "When there will never be a randomized controlled trial." Kidney international 88, no. 2 (August 2015): 220-222.

PMID
26230199
Full Text

Wolf, M, and Bushinsky, DA. "Bones and stones, edition 2015." Current Opinion in Nephrology and Hypertension (June 2015): 1-1.

Full Text

Wolf, M. "The Biomarker Niche for Fibroblast Growth Factor 23 Testing in CKD." Journal of the American Society of Nephrology 26, no. 1 (January 1, 2015): 7-9.

Full Text

Wolf, M. "In Search of the Fountain of Youth." Journal of the American Society of Nephrology 25, no. 10 (October 1, 2014): 2143-2145.

Full Text

Wolf, M, and Bushinsky, DA. "Innovations in bones and stones." Current Opinion in Nephrology and Hypertension 22, no. 4 (July 2013): 369-370.

Full Text